Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and cardiometabolic diseases, leveraging AI and extensive human datasets.

Jan 8 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for ...

Novo Nordisk has almost doubled the scale of an R&D alliance with Valo Health – a specialist in applying artificial intelligence to drug discovery – adding up to nine programmes to the ...

Under the expanded partnership, Novo Nordisk has agreed to pay Valo $190 million upfront, up-to-$4.6 billion in milestones, plus R&D funding and potential royalty payments. “This level of ...

Novo Nordisk’s collaboration with artificial intelligence startup Valo Health has focused on developing new drugs for cardiovascular disease. The pharmaceutical giant likes what it’s seen so ...

Novo Nordisk NOVO.B-0.18%decrease; red down pointing triangle expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...

Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted fourth-quarter operating profit above expectations as it ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo’s Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition ...